{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:37:03Z","timestamp":1791416223770,"version":"4.3.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012331","name":"LEO Fondet","doi-asserted-by":"publisher","award":["LF16117"],"award-info":[{"award-number":["LF16117"]}],"id":[{"id":"10.13039\/501100012331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13346-025-01907-8","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:17:52Z","timestamp":1750940272000},"page":"2130-2141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous pharmacokinetics of a volatile drug post-application to the skin"],"prefix":"10.1007","volume":"16","author":[{"given":"Andrea","family":"Pensado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Zarmpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette L.","family":"Bunge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2233-7654","authenticated-orcid":false,"given":"M. Bego\u00f1a","family":"Delgado-Charro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"1907_CR1","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2020.0567","author":"A Rabindranathnambi","year":"2021","unstructured":"Rabindranathnambi A, Abid M. Topical treatments in dermatology. Br J Hosp Med (Lond). 2021. https:\/\/doi.org\/10.12968\/hmed.2020.0567.","journal-title":"Br J Hosp Med (Lond)"},{"key":"1907_CR2","unstructured":"FDA. Code of Federal Regulations. 2018. https:\/\/www.govinfo.gov\/content\/pkg\/CFR-2024-title21-vol5\/pdf\/CFR-2024-title21-vol5-sec314-3.pdf. Accessed 14 March 2025."},{"key":"1907_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2022.02.007","author":"SG Raney","year":"2022","unstructured":"Raney SG, Ghosh P, Ramezanli T, Lehman PA, Franz TJ. Cutaneous pharmacokinetic approaches to compare bioavailability and\/or bioequivalence for topical drug products. Dermatol Clin. 2022. https:\/\/doi.org\/10.1016\/j.det.2022.02.007","journal-title":"Dermatol Clin"},{"key":"1907_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2018.07.050","author":"M Miranda","year":"2018","unstructured":"Miranda M, Sousa JJ, Veiga F, Cardoso C, Vitorino C. Bioequivalence of topical generic products. Part 1: where are we now? Eur J Pharm Sci. 2018. https:\/\/doi.org\/10.1016\/j.ejps.2018.07.050.","journal-title":"Eur J Pharm Sci"},{"key":"1907_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0292-0","author":"SG Raney","year":"2015","unstructured":"Raney SG, Franz TJ, Lehman PA, Lionberger R, Chen ML. Pharmacokinetics-Based approaches for bioequivalence evaluation of topical dermatological drug products. Clin Pharmacokinet. 2015. https:\/\/doi.org\/10.1007\/s40262-015-0292-0.","journal-title":"Clin Pharmacokinet"},{"key":"1907_CR6","unstructured":"FDA. Product-Specific Guidances for Generic Drug Development. 2022. https:\/\/www.fda.gov\/drugs\/guidances-drugs\/product-specific-guidances-generic-drug-development. Accessed 05 November 2024."},{"key":"1907_CR7","unstructured":"EMA. Guideline on quality and equivalence of locally applied, locally acting cutaneous products. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-equivalence-locally-applied-locally-acting-cutaneous-products_en.pdf. Accessed 05 November 2024."},{"key":"1907_CR8","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9411-0","author":"RK Chang","year":"2013","unstructured":"Chang RK, Raw A, Lionberger R, Yu L. Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products. AAPS J. 2013. https:\/\/doi.org\/10.1208\/s12248-012-9411-0.","journal-title":"AAPS J"},{"key":"1907_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.062","author":"SG Raney","year":"2020","unstructured":"Raney SG, Luke MC. A new paradigm for topical generic drug products: impact on therapeutic access. J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.062.","journal-title":"J Am Acad Dermatol"},{"key":"1907_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-020-02042-9","author":"MC Kwa","year":"2020","unstructured":"Kwa MC, Tegtmeyer K, Welty LJ, Raney SG, Luke MC, Xu S, et al. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products. Arch Dermatol Res. 2020. https:\/\/doi.org\/10.1007\/s00403-020-02042-9.","journal-title":"Arch Dermatol Res"},{"key":"1907_CR11","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9679-3","author":"AC Braddy","year":"2015","unstructured":"Braddy AC, Davit BM, Stier EM, Conner DP. Survey of international regulatory bioequivalence recommendations for approval of generic topical dermatological drug products. AAPS J. 2015. https:\/\/doi.org\/10.1208\/s12248-014-9679-3.","journal-title":"AAPS J"},{"key":"1907_CR12","unstructured":"FDA. Physicochemical and structural (Q3) characterization of topical drug products: Submitted in ANDAs Guidance for Industry. 2022. https:\/\/www.fda.gov\/media\/162471\/download. Accessed 26 October 2023."},{"key":"1907_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105082","author":"M Miranda","year":"2020","unstructured":"Miranda M, Cardoso C, Vitorino C. Quality and equivalence of topical products: A critical appraisal. Eur J Pharm Sci. 2020. https:\/\/doi.org\/10.1016\/j.ejps.2019.105082.","journal-title":"Eur J Pharm Sci"},{"key":"1907_CR14","unstructured":"FDA. In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs. Guidance for Industry. 2022. https:\/\/www.fda.gov\/media\/162476\/download. Accessed 14 March 2025."},{"key":"1907_CR15","unstructured":"NIHS. Guideline for Bioequivalence Studies of Generic Products for Topical Use. 2003. https:\/\/www.nihs.go.jp\/drug\/be-guide%28e%29\/Topical_BE-E.pdf. Accessed 14 March 2025."},{"key":"1907_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2707-3","author":"A Pensado","year":"2019","unstructured":"Pensado A, Chiu WS, Cordery SF, Rantou E, Bunge AL, Delgado-Charro MB, et al. Stratum corneum sampling to assess bioequivalence between topical acyclovir products. Pharm Res. 2019. https:\/\/doi.org\/10.1007\/s11095-019-2707-3.","journal-title":"Pharm Res"},{"key":"1907_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.06.063","author":"SF Cordery","year":"2017","unstructured":"Cordery SF, Pensado A, Chiu WS, Shehab MZ, Bunge AL, Delgado-Charro MB, et al. Topical bioavailability of diclofenac from Locally-Acting, dermatological formulations. Int J Pharm. 2017. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.06.063.","journal-title":"Int J Pharm"},{"key":"1907_CR18","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00571-3","author":"M Hoppel","year":"2021","unstructured":"Hoppel M, Tabosa MAM, Bunge AL, Delgado-Charro MB, Guy RH. Assessment of drug delivery kinetics to epidermal targets in vivo. AAPS J. 2021. https:\/\/doi.org\/10.1208\/s12248-021-00571-3.","journal-title":"AAPS J"},{"key":"1907_CR19","unstructured":"FDA. Topical Dermatologic Corticosteroids: In Vivo Bioequivalence: Guidance for Industry. 2023. https:\/\/www.fda.gov\/media\/162457\/download. Accessed 14 March 2025."},{"key":"1907_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4899-1262-6_8","volume-title":"Topical drug bioavailability, bioequivalence, and penetration","author":"EW Smith","year":"1993","unstructured":"Smith EW, Meyer E, Haigh JM. The human skin blanching assay for topical corticosteroid bioavailability assessment. In: Shah VP, Maibach HI, editors. Topical drug bioavailability, bioequivalence, and penetration. Boston, MA.: Springer; 1993. pp. 155\u201362."},{"key":"1907_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0442-z","author":"M Bodenlenz","year":"2017","unstructured":"Bodenlenz M, Tiffner KI, Raml R, Augustin T, Dragatin C, Birngruber T, et al. Open flow microperfusion as a dermal Pharmacokinetic approach to evaluate topical bioequivalence. Clin Pharmacokinet. 2017. https:\/\/doi.org\/10.1007\/s40262-016-0442-z.","journal-title":"Clin Pharmacokinet"},{"key":"1907_CR22","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c01109","author":"MA Maciel Tabosa","year":"2023","unstructured":"Maciel Tabosa MA, Vitry P, Zarmpi P, Bunge AL, Belsey NA, Tsikritsis D, et al. Quantification of chemical uptake into the skin by vibrational spectroscopies and stratum corneum sampling. Mol Pharm. 2023. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c01109.","journal-title":"Mol Pharm"},{"key":"1907_CR23","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00755","author":"P Zarmpi","year":"2023","unstructured":"Zarmpi P, Tabosa MAM, Vitry P, Bunge AL, Belsey NA, Tsikritsis D, et al. Confocal Raman spectroscopic characterization of dermatopharmacokinetics ex vivo. Mol Pharm. 2023. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00755.","journal-title":"Mol Pharm"},{"key":"1907_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-00988-5","author":"SC Yeoh","year":"2022","unstructured":"Yeoh SC, Goh CF. Topical delivery of salicylates. Drug Deliv Transl Res. 2022. https:\/\/doi.org\/10.1007\/s13346-021-00988-5.","journal-title":"Drug Deliv Transl Res"},{"key":"1907_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/0002889758507348","author":"WA Fishbeck","year":"1975","unstructured":"Fishbeck WA, Langner RR, Kociba RJ. Elevated urinary phenol levels not related to benzene exposure. Am Ind Hyg Assoc J. 1975. https:\/\/doi.org\/10.1080\/0002889758507348.","journal-title":"Am Ind Hyg Assoc J"},{"key":"1907_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.04.079","author":"WM Lau","year":"2012","unstructured":"Lau WM, Ng KW, Sakenyte K, Heard CM. Distribution of esterase activity in Porcine ear skin, and the effects of freezing and heat separation. Int J Pharm. 2012. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.04.079.","journal-title":"Int J Pharm"},{"key":"1907_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13080934","author":"KC Telaprolu","year":"2023","unstructured":"Telaprolu KC, Grice JE, Mohammed YH, Roberts MS. Human skin drug metabolism: relationships between Methyl salicylate metabolism and esterase activities in IVPT skin membranes. Metabolites. 2023. https:\/\/doi.org\/10.3390\/metabo13080934.","journal-title":"Metabolites"},{"key":"1907_CR28","unstructured":"Mentholatum. Deep Heat Rub. 2009. https:\/\/www.boots.com\/wcsstore\/ExtendedSitesCatalogAssetStore\/Attachment%2FProduct_PatientLeaflets%2F10007387-deep_heat_heat_rub.pdf?srsltid=AfmBOooE7zBW2hslNrNIQzpHV1Bgp4ltK4SATYaUogdtnHQP7OBtMPdY. Accessed 14 March 2025."},{"key":"1907_CR29","unstructured":"Mentholatum. Deep Heat Max. 2022. https:\/\/www.boots.com\/wcsstore\/ExtendedSitesCatalogAssetStore\/Attachment%2FProduct_PatientLeaflets%2F10021931%20Deep%20Heat%20PIL%2018.07.pdf?srsltid=AfmBOopwmqxnAPh0vTm-dWglqm2uHCaX6-siy4aFvC2i4kl-04DVE-Y6. Accessed 14 March 2025."},{"key":"1907_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.supflu.2020.105013","author":"Y Sugimoto","year":"2020","unstructured":"Sugimoto Y, Ota M, Sato Y, Smith RL, Inomata H. Distribution coefficients of Salicylic acid and Methyl salicylate in high-pressure CO2\u2013 water - ethanol systems. J Supercrit Fluids. 2020. https:\/\/doi.org\/10.1016\/j.supflu.2020.105013.","journal-title":"J Supercrit Fluids"},{"key":"1907_CR31","unstructured":"SPI supplies, Parafilm M. https:\/\/www.2spi.com\/category\/parafilm-m\/parafilm\/. Accessed 29 May 2025."},{"key":"1907_CR32","doi-asserted-by":"publisher","unstructured":"Herkenne C, Alberti I, Naik A, Kalia YN, Mathy F-X, Pr\u00e9at V et al. In Vivo Methods for the Assessment of Topical Drug Bioavailability. Pharm Res. 2008; https:\/\/doi.org\/10.1007\/s11095-007-9429-7","DOI":"10.1007\/s11095-007-9429-7"},{"key":"1907_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9742-9","author":"B Dri-Stempfer","year":"2009","unstructured":"N\u2019, Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res. 2009. https:\/\/doi.org\/10.1007\/s11095-008-9742-9.","journal-title":"Pharm Res"},{"key":"1907_CR34","first-page":"117","volume":"8","author":"GA Shabir","year":"2011","unstructured":"Shabir GA, Bradshaw TK. Development and validation of a liquid chromatography method for the determination of Methyl salicylate in a medicated cream formulation. Turk J Pharm Sci. 2011;8:117\u201326.","journal-title":"Turk J Pharm Sci"},{"key":"1907_CR35","first-page":"85","volume":"11","author":"T Higuchi","year":"1960","unstructured":"Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem. 1960;11:85\u201397.","journal-title":"J Soc Cosmet Chem"},{"key":"1907_CR36","unstructured":"FDA. FY 2023 GDUFA Science and research report. 2023. https:\/\/www.fda.gov\/media\/178640\/download#page=40. Accessed 05 November 2024."},{"key":"1907_CR37","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00238","author":"A Pensado","year":"2021","unstructured":"Pensado A, Hattam L, White KAJ, McGrogan A, Bunge AL, Guy RH, et al. Skin pharmacokinetics of transdermal scopolamine: measurements and modeling. Mol Pharm. 2021. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00238.","journal-title":"Mol Pharm"},{"key":"1907_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03199-w","author":"S Shukla","year":"2022","unstructured":"Shukla S, Bunge AL, Hassan HE, Stinchcomb AL. Investigator impact on reproducibility of drug bioavailability in stratum corneum sampling by tape stripping. Pharm Res. 2022. https:\/\/doi.org\/10.1007\/s11095-022-03199-w.","journal-title":"Pharm Res"},{"key":"1907_CR39","unstructured":"Sigma. Parafilm M. https:\/\/www.sigmaaldrich.com\/deepweb\/assets\/sigmaaldrich\/product\/documents\/194\/913\/p7793pis.pdf. Accessed 29 May 2025."},{"key":"1907_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1347196","author":"N Versteeg","year":"2024","unstructured":"Versteeg N, Wellauer V, Wittenwiler S, Aerenhouts D, Clarys P, Clijsen R. Short-term cutaneous vasodilatory and thermosensory effects of topical Methyl salicylate. Front Physiol. 2024. https:\/\/doi.org\/10.3389\/fphys.2024.1347196.","journal-title":"Front Physiol"},{"key":"1907_CR41","doi-asserted-by":"publisher","unstructured":"Bunge AL, N\u2019Dri-Stempfer B, Navidi WC, Guy RH. Therapeutic Equivalence of Topical Products, Final Report, Award No. 223-04-3004. Department of Health and Human Services, Food and Drug Administration. 2007; https:\/\/doi.org\/10.13140\/RG.2.2.24102.55368","DOI":"10.13140\/RG.2.2.24102.55368"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01907-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01907-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01907-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:49:47Z","timestamp":1782305387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01907-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1907"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01907-8","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"18 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of theresponsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 [\n                      \n                      ]. The protocol was approved by the Research Ethics Approval Committee for Health at the University of Bath (REACH EP 18\/19 061). Informed written consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have approved submission of this work and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}